Testing effectiveness (Phase 2)Looking for participantsNCT06827613
What this trial is testing
Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
Who this might be right for
Triple Negative Locally Advanced Non-resectable Breast CancerHR+, HER2-, Advanced Breast Cancer
Marengo Therapeutics, Inc. 50